Remdesivir shows promise in severe COVID-19 patients
NCT ID NCT04365725
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 84 hospitalized adults with severe COVID-19 who received the drug remdesivir. Researchers analyzed their recovery over 15 days to see how the drug affected their clinical course. The goal was to understand if remdesivir helps improve outcomes in severe cases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remdesivir
- What this could lead to
- If successful, this could confirm remdesivir as a treatment to help hospitalized COVID-19 patients recover faster.
- What could go wrong
- This is a small, retrospective study without a control group, so results may not be definitive. Remdesivir has shown mixed results in other trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Cochin
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?